Takeda Says Japan Approves CUVITRU Subcutaneous Immunoglobulin For Patients With Agammaglobulinemia

RTTNews | 705天前
Takeda Says Japan Approves CUVITRU Subcutaneous Immunoglobulin For Patients With Agammaglobulinemia

(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK) announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in patients aged 2 years and older with agammaglobulinemia or hypogammaglobulinemia disorders.

This is characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immunodeficiency (SID).

The approval marks Takeda's first subcutaneous immunoglobulin (SCIG) therapy for patients in Japan.

The approval is based on results from a Phase 3 clinical trial that evaluated the efficacy, safety, tolerability and pharmacokinetics of CUVITRU in Japanese patients with PID, as well as two Phase 2/3 clinical trials conducted in patients with PID in North America and Europe.

Results from the clinical trial in 17 patients in Japan confirmed its efficacy and safety profile and CUVITRU was well-tolerated. Previously reported clinical trial results also confirmed the efficacy and safety of CUVITRU.

read more
Takeda Says FDA Approves EOHILIA To Treat Eosinophilic Esophagitis

Takeda Says FDA Approves EOHILIA To Treat Eosinophilic Esophagitis

Japan's Takeda Pharmaceutical Co. Ltd. (TAK) announced Monday that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE)1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.
RTTNews | 565天前
Takeda Canada Inks Contract With Canadian Blood Services For GLASSIA

Takeda Canada Inks Contract With Canadian Blood Services For GLASSIA

Takeda Canada Inc., the Canadian arm of Japan's Takeda Pharmaceutical Co. Ltd. (TAK) on Wednesday entered into a contract with Canadian Blood Services (CBS) for GLASSIA (alpha-1 proteinase inhibitor) resulting from CBS's request for proposal for hereditary deficiency of Alpha-1 Antitrypsin Deficiency (Alpha-1).
RTTNews | 619天前
Takeda Says FDA Accepts BLA For ENTYVIO For Maintenance Therapy In Crohn's Disease

Takeda Says FDA Accepts BLA For ENTYVIO For Maintenance Therapy In Crohn's Disease

Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the investigational subcutaneous (SC) administration of ENTYVIO (vedolizumab) for maintenance therapy in adults with moderately to severely active Crohn's disease (CD) after induction therapy with ENTYVIO intravenous (IV).
RTTNews | 717天前
German Inflation Accelerates To 2.2% In August

German Inflation Accelerates To 2.2% In August

Consumer price inflation in Germany climbed in August to its highest level in five months, while the core figure was steady amid an acceleration in food price growth, and weakened chances for further easing from the European Central Bank in the near term.
RTTNews | 17小时22分钟前
Swiss Market Ends Modestly Lower

Swiss Market Ends Modestly Lower

Save for a very brief while early on in the session, and for less than an hour a little past mid afternoon, the Switzerland market stayed in negative territory on Friday with investors largely staying cautious due to a lack of positive triggers.
RTTNews | 20小时12分钟前